MIRAPEX Drug Patent Profile

When do Mirapex patents expire, and what generic alternatives are available?

Mirapex is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in MIRAPEX is pramipexole dihydrochloride. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the pramipexole dihydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mirapex

A generic version of MIRAPEX was approved as pramipexole dihydrochloride by ZYDUS PHARMS USA INC on July 6^th, 2010.

Summary for MIRAPEX

US Patents:	0
Applicants:	1
NDAs:	2

Paragraph IV (Patent) Challenges for MIRAPEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MIRAPEX	Tablets	pramipexole dihydrochloride	0.75 mg	020667	1	2008-07-31
MIRAPEX	Tablets	pramipexole dihydrochloride	0.125 mg, 0.5 mg, 1 mg and 1.5 mg	020667	1	2005-06-24
MIRAPEX	Tablets	pramipexole dihydrochloride	0.25 mg	020667	1	2005-05-27

US Patents and Regulatory Information for MIRAPEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-001	Jul 1, 1997		DISCN	Yes	No
Boehringer Ingelheim	MIRAPEX ER	pramipexole dihydrochloride	TABLET, EXTENDED RELEASE;ORAL	022421-007	Jun 17, 2011		DISCN	Yes	No	8,679,533		Y
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-005	Jul 1, 1997		DISCN	Yes	No
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-007	Jul 30, 2007		DISCN	Yes	No

International Patents for MIRAPEX

See the table below for patents covering MIRAPEX around the world.

Country	Patent Number	Title	Estimated Expiration
Slovakia	284264
Spain	550235
Portugal	989850
Spain	8707514

Supplementary Protection Certificates for MIRAPEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0186087	98C0013	Belgium		PRODUCT NAME: PRAMIPEXOL; REGISTRATION NO/DATE: EU/1/97/050/001 19971014
0186087	SPC/GB98/017	United Kingdom		PRODUCT NAME: PRAMIPEXOLE, OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT, IN PARTICULAR PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE; REGISTERED: UK EU/1/97/050/001 19971014; UK EU/1/97/050/002 19971014; UK EU/1/97/050/003 19971014; UK EU/1/97/050/004 19971014; UK EU/1/97/050/005 19971014; UK EU/1/97/050/006 19971014; UK EU/1/97/050/007 19971014; UK EU/1/97/050/008 19971014; UK EU/1/97/050/009 19971014; UK EU/1/97/050/010 19971014
0186087	C980002	Netherlands		PRODUCT NAME: PRAMIPEXOL, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER PRAMIPEXOL-DIHYDROCHLORIDE-MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/97/050/001 - EU/1/97/050/010 19971014

Investment Scenario, Market Dynamics, and Financial Trajectory for MIRAPEX (Pramipexole)

Last updated: February 3, 2026

Summary

MIRAPEX (pramipexole) is a dopamine agonist developed by Boehringer Ingelheim, primarily approved for the treatment of Parkinson’s disease and restless legs syndrome (RLS). Marketed since 1997, MIRAPEX remains a cornerstone in therapy but faces competitive pressures from newer pharmacologic options and biosimilars. This analysis evaluates the investment outlook, market trends, and financial trajectory of MIRAPEX, incorporating key data points, competitive landscape, regulatory environment, and future growth prospects.

Introduction

Key facts:

Attribute	Details
Active Ingredient	Pramipexole
Approved Indications	Parkinson's disease, restless legs syndrome (RLS)
Initial Approval Date	1997 (FDA)
Marketed By	Boehringer Ingelheim
Estimated Global Market Size	$1.1 billion (2022)
Patent Status	Expired/licensing granted; no active patent protection in key markets

---

Investment Scenario for MIRAPEX

Market Position and Revenue Profile

Factor	Details
Revenue (2022)	Approx. $200 million globally (Boehringer Ingelheim, estimates)
Primary Markets	United States, Europe, Japan
Licensing Agreements	Licensees in emerging markets, some biosimilar development initiatives
Revenue Trends	Declining, due to patent expiry and biosimilar entry
CAGR (2018-2022)	Approximately -4%
Market Penetration	High in early 2000s, plateaued as newer agents emerged

Stakeholder and Competitive Landscape

Competitors	Key Drugs	Market Share (estimated)	Patent Status
Rotigotine (Neupro)	Rotigotine transdermal patch	~25%	Patent protected until 2024/2027
Ropinirole (Requip)	Ropinirole oral	~20%	Patent expired (2018)
Rotigotine, Ropinirole, others	Multiple generics & biosimilars	Remaining ~55%	Biosimilars/originals

Investment Risks and Opportunities

Risks	Opportunities
Patent expiry and biosimilar competition	Expansion into emerging markets via licensing
Competition from new therapies	Combination therapies and new indications
Regulatory challenges	Fast-track approvals or new formulations
Market saturation	Growing RLS prevalence, aging populations

---

Market Dynamics Influencing MIRAPEX’s Trajectory

Patent and Regulatory Environment

Timeline	Milestones
Patent expiry	US patent expired in 2018; EU patent expired in 2019
Biosimilar approvals	Several biosimilars approved in Europe since 2020
Patent litigation & extensions	No recent patent litigations; minor legal challenges planned or ongoing

Pricing and Reimbursement Trends

Region	Trends	Impact on Revenue
US	Increasing emphasis on biosimilars and generics for cost-saving	Downward pricing pressure
EU	Maximize reimbursement through health authorities	Price erosion, discounting
Japan	Favorable pricing; aging population sustains demand	Stable revenue in local markets

Global Disease Burden & Market Growth Drivers

Disease/Condition	Prevalence/Incidence	Market Growth Drivers
Parkinson’s disease	10 million globally (2020 estimate), projected to increase to 12 million by 2040	Aging populations, diagnostic improvements
Restless legs syndrome (RLS)	7-10% of adults, European prevalence studies	Increased awareness, wider diagnosis

Drug Development and Innovation Trends

Trend	Impact
Development of biosimilars	Increased competition, reduced pricing
Combination therapies	Potential for improved efficacy, new indications
Digital health integration	Monitoring and adherence enhancements
Novel delivery systems	Transdermal patches, prolonged-release formulations

---

Financial Trajectory and Future Revenues

Historical Revenue Breakdown (Approximate)

Years	US Revenue	EU Revenue	Rest of World	Total Revenue
2018	$250 million	$100 million	$50 million	$400 million
2019	$220 million	$90 million	$45 million	$355 million
2020	$210 million	$85 million	$40 million	$335 million
2021	$200 million	$80 million	$35 million	$315 million
2022	$200 million	$70 million	$30 million	$300 million

Projection (2023-2027)

Year	Expected Revenue Range	Key Factors
2023	$180-210 million	Biosimilar entries, market saturation
2024	$160-200 million	Patent expiries, pricing pressure
2025	$150-180 million	Increased biosimilar adoption, new markets
2026	$140-170 million	Competitive intensity, market adaptation
2027	$130-160 million	Mature market, possible pipeline launches

Potential Revenue Impact of Biosimilars

Scenario	Impact on MIRAPEX Revenue	Assumptions
Aggressive biosimilar entry	$50-70 million loss annually	50% market share taken in Europe, moderate in US
Limited biosimilar penetration	$20-30 million loss annually	High brand loyalty, delayed biosimilar adoption in some regions

---

Comparison with Similar Agents

Agent	Indication	Patent Status	Market Share (2022)	Key Attributes
Rotigotine (Neupro)	Parkinson’s & RLS	Patent expiry in 2024/2027	~25%	Transdermal delivery, approved in 2006
Ropinirole (Requip)	Parkinson’s & RLS	Patent expired, generic available	~20%	Oral formulation, established safety profile
Apomorphine (Apokyn)	Parkinson’s (advanced cases)	Patent pending or expired	<5%	Injectable, for advanced Parkinson’s

Regulatory and Policy Considerations

Policy Area	Impact on MIRAPEX	Status/Details
Patent laws and extensions	Can delay biosimilar competition	US and EU patent laws enable interim protections
Price regulation in healthcare markets	Pressure on drug pricing	US Medicare/Medicaid, European HTA bodies
Approval pathways for biosimilars	Easier entry for biosimilar drugs	FDA, EMA fast-track pathways
Orphan drug status, if applicable	Less relevant; off-label use limited	Not applicable now

---

Key Challenges and Strategic Considerations

1. Patent Expiry and Biosimilar Competition: The primary challenge for MIRAPEX’s sustained revenue comes from biosimilar and generic entries, especially post-2018/2019 expirations. Market share erosion is to be expected as biosimilars gain approval and market acceptance.

2. Market Saturation: Established markets like the US and Europe display saturation; revenue decline reflects limited growth potential without new indications or formulations.

3. Emerging Market Opportunities: Licensing agreements and local partnerships in Asia, Latin America, and Africa could provide incremental growth, compensating for mature market decline.

4. Pipeline and Innovation: Currently, MIRAPEX lacks a direct pipeline. Investment efforts should focus on developing new formulations, extended-release versions, or combination therapies.

Conclusion and Investment Outlook

Aspect	Summary
Market Outlook	Declining revenues post-patent expiry; potential stabilization via licensing and emerging markets
Competitive Landscape	Rising biosimilar competition, shifting market dynamics
Regulatory Environment	Favorable for biosimilars, yet sensitive pricing trends
Financial Trajectory	Revenue expected to decline gradually, with potential stabilization in emerging markets
Investment Viability	Short to medium-term decline; long-term depends on pipeline innovation and licensing strategies

---

Key Takeaways

• MIRAPEX's revenue has declined approximately 4-5% annually since 2018, driven by patent expiry and biosimilar entry.
• The global market is consolidating, with biosimilars expected to dominate in mature markets within the next 2-3 years.
• Future growth hinges on expansion into emerging markets, licensing strategies, or pipeline renewal.
• Competitive pressure from agents like Rotigotine (Neupro) and Ropinirole (Requip) complicates market share retention.
• Strategic investments in development of new formulations and indications could mitigate revenue erosion.

---

FAQs

1. What is the current patent status of MIRAPEX?

MIRAPEX’s primary patent protection in the US expired in 2018, with European patents expiring in 2019. No recent patent extensions or new patents have been granted for the core formulation, opening pathways for biosimilar competition.

2. How does the entry of biosimilars affect MIRAPEX’s market share?

Biosimilars, particularly in Europe and Asia, are expected to capture significant portions of the market, reducing MIRAPEX’s revenue by an estimated 30-50% over the next 3-5 years, especially where biosimilar acceptance is higher.

3. Are there regulatory initiatives that could extend MIRAPEX’s profitability?

While no current extension applications are reported, regulatory pathways favoring biosimilars and fast-track approvals in certain regions may expedite generic competition, further impacting MIRAPEX’s market share.

4. Which regions offer the most growth potential for MIRAPEX?

Emerging markets, including China, India, and Latin America, present growth opportunities via licensing agreements, off-label expansion, and price-sensitive consumer segments, offsetting saturation in mature markets.

5. What strategic moves should stakeholders consider regarding MIRAPEX?

Stakeholders should evaluate licensing, pipeline ventures, and market expansion in emerging economies, while preparing for biosimilar-induced revenue declines through cost optimization and alternative therapies development.

---

References

[1] Boehringer Ingelheim. (2022). MIRAPEX (pramipexole) product information.
[2] MarketWatch. (2022). Global Parkinson’s Disease Treatment Market Report.
[3] European Medicines Agency. (2023). Biosimilar approvals and policy frameworks.
[4] IQVIA. (2022). Pharmaceutical market analysis and trends.
[5] PubMed. (2021). Epidemiology of Restless Legs Syndrome and Parkinson’s Disease.